Emile E. Voest

38.0k citations

370 papers · 18.8k indexed · 8 hit papers · h-index 70

Cancer Research top 0.1%
- Cancer Genomics and Diagnostics 74
- Cancer, Hypoxia, and Metabolism 51
Oncology top 0.1%
- Colorectal Cancer Treatments and Studies 51
- Cancer Treatment and Pharmacology 47
- Cancer Cells and Metastasis 29
- Cancer Immunotherapy and Biomarkers 21
Hepatology top 1%
Molecular Biology top 0.5%
- Angiogenesis and VEGF in Cancer 55
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations 31

Co-authors: Jeanine M.L. Roodhart Martijn F.B.G. Gebbink Alexander de Graeff Saskia Teunissen Krijn K. Dijkstra René H. Medema Rachel H. Giles Judah Folkman
Cited by: Cancer Research Oncology Hepatology
Journals: Journal of Clinical Oncology (47 papers)Annals of Oncology (30 papers)Clinical Cancer Research (15 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Emile E. Voest

364 papers receiving 18.4k citations

Hit Papers

8 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2024 Cell
2022 Nature Medicine
2021 Cancer Cell
2018 Nature Medicine
2017 Cell chemical biology
2009 New England Journal of Medicine
2007 Journal of Pain and Symptom Management
1995 JNCI Journal of the National Cancer Institute

Peers

Countries citing papers authored by Emile E. Voest

Since Specialization

Citations

This map shows the geographic impact of Emile E. Voest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emile E. Voest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emile E. Voest more than expected).

Fields of papers citing papers by Emile E. Voest

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emile E. Voest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emile E. Voest. The network helps show where Emile E. Voest may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Emile E. Voest, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Emile E. Voest Line = papers co-authored together Emile E. Voest links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Clinical Cancer Research ·Мягдиева Ильсея Ринатовна,杨翠兰,Laurien J. Zeverijn,Birgit S. Geurts,Wu Yun,Gijs F. de Wit,Paul Roepman,Anne M.L. Jansen,Vincent van der Noort,Egbert F. Smit,Ann Hoeben,Lizza Hendriks,Michel M. van den Heuvel,Berber Piet,Gerarda J.M. Herder,Sayed M.S. Hashemi,Hans Gelderblom,Henk M.W. Verheul,Emile E. Voest,Adrianus J. de Langen	2024	1
2	Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol Clinical Cancer Research ·Jade M. van Berge Henegouwen,Laurien J. Zeverijn,Birgit S. Geurts,Louisa R. Hoes,Hanneke van der Wijngaart,Vincent van der Noort,Alwin D. R. Huitema,Filip De Vos,Katrien Grünberg,Haiko J. Bloemendal,Henk M.W. Verheul,Emile E. Voest,Hans Gelderblom	2024	1
3	1630P Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers Annals of Oncology ·Shohnoza Nazirjonova,Antonio Mulero‐Sánchez,Jun Kuno,Astrid Bosma,René Bernards,Alwin D. R. Huitema,Emile E. Voest,Sara Mainardi,Frans L. Opdam	2023	2
4	1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP) Annals of Oncology ·Karin Verkerk,袁孝尚,Laurien J. Zeverijn,Birgit S. Geurts,Wu Yun,Jiaru Hu,Paul Roepman,Anne M.L. Jansen,Vincent van der Noort,Egbert F. Smit,Ann Hoeben,Lizza Hendriks,Carla M.L. van Herpen,Berber Piet,Christine Ann Linde,Sayed M.S. Hashemi,Hans Gelderblom,Henk M.W. Verheul,Emile E. Voest,J. De Langen	2023	3
5	1711P The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine Annals of Oncology ·Hans Gelderblom,Anders Edsjö,Elizabeth Estabrook,Ulrik Lassen,Åslaug Helland,Ifueko Mercy Moses-Otutu,Bettina Ryll,Iwona Ługowska,Jean‐Yves Blay,Ragnhild Sørum Falk,Sahar Barjesteh van Waalwijk van Doorn-Khosrovani,Katarina Steen Carlsson,Katriina Peltola,Albrecht Stenzinger,Eduard Vrdoljak,Júlio Oliveira,H.A. Powers,Henk M.W. Verheul,Emile E. Voest,Kjetil Taskén	2023	1
6	Delivering precision oncology to patients with cancerbreakdown → Nature Medicine ·Joaquı́n Mateo,Lotte Steuten,Philippe Aftimos,Fabrice André,D. M. Davies,Elena Garralda,Jan Geißler,Don Husereau,H. Miron,Nicola Normanno,Jorge S. Reis‐Filho,Stephen Stefani,David M. Thomas,C. Benedikt Westphalen,Emile E. Voest	2022	197
7	Can Drug Repurposing Accelerate Precision Oncology? Cancer Discovery ·Luuk J. Schipper,Laurien J. Zeverijn,Mathew J. Garnett,Emile E. Voest	2022	24
8	Limited evolution of the actionable metastatic cancer genome under therapeutic pressure Nature Medicine ·Joris van de Haar,Louisa R. Hoes,Paul Roepman,Martijn P. Lolkema,Henk M.W. Verheul,Hans Gelderblom,Adrianus J. de Langen,Egbert F. Smit,Edwin Cuppen,Lodewyk F.A. Wessels,Emile E. Voest	2021	36
9	Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity Molecular Cancer Research ·Adji Sastrosupadi Sastrosupadi,S. Tayal,Markus J. van Roosmalen,Nizar Hami,Ingrid Verlaan-Klink,Harmjan R. Vos,Robert M. van Es,Marco J. Koudijs,Emile E. Voest,Hugo J.G. Snippert,Wigard P. Kloosterman	2020	11
10	Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing Nature Communications ·Adji Sastrosupadi Sastrosupadi,Sam de Blank,Ivo Renkens,Liset Westera,J R Sutherst,Jose Espejo Valle-Inclán,Rocío Chamorro González,Anton G. Henssen,Markus J. van Roosmalen,Ronald W. Stam,Emile E. Voest,Wigard P. Kloosterman,Gijs van Haaften,Glen R. Monroe	2020	47
11	A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer Cancer Research ·Wigard P. Kloosterman,Robert R.J. Coebergh van den Braak,Mark Pieterse,Markus J. van Roosmalen,Anieta M. Sieuwerts,Adji Sastrosupadi Sastrosupadi,Perlis. Jabatan Mufti Negeri,Zarina S. Lalmahomed,Salo Ooft,Anne van Galen,Marcel Smid,Aurel Mihail Titu,Fried Zwartkruis,John W.M. Martens,John A. Foekens,Katharina Biermann,Marco J. Koudijs,Jan N.M. IJzermans,Emile E. Voest	2017	67
12	Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts EMBO Molecular Medicine ·Kristel Kemper,Oscar Krijgsman,Paulien Cornelissen‐Steijger,Aida Shahrabi,Fleur Weeber,Ji‐Ying Song,Thomas Kuilman,Daniël J. Vis,Lodewyk F.A. Wessels,Emile E. Voest,Ton N. Schumacher,Christian U. Blank,David J. Adams,John B.A.G. Haanen,Daniel S. Peeper	2015	103
13	Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study Clinical Cancer Research ·Víctor Moreno,David Olmos,Carlos Gomez‐Roca,Philippe A. Cassier,Rafael Morales‐Barrera,Bierma-Zeinstra SMA,Elisa Gallerani,André T. Brunetto,Patrick Schöffski,Silvia Marsoni,Jan H.M. Schellens,Nicolas Penel,Emile E. Voest,Jeffrey Evans,Ruth Plummer,Richard H. Wilson,Jean Charles Soria,Josep Tabernero,Jaap Verweij,Stan B. Kaye	2014	14
14	Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment Clinical Cancer Research ·Joost S.P. Vermaat,Isaäc J. Nijman,Marco J. Koudijs,Lauren F Bowen,Stefan Scherer,Michal Mokrý,Wijnand Roessingh,Nico Lansu,Ewart de Bruijn,Richard van Hillegersberg,P. J. van Diest,Edwin Cuppen,Emile E. Voest	2011	119
15	Chemotherapy Enhances Metastasis Formation via VEGFR-1–Expressing Endothelial Cells Cancer Research ·Laura G.M. Daenen,Jeanine M.L. Roodhart,Miranda van Amersfoort,Nuning Susilowati,Wijnand Roessingh,Laurien H. Ulfman,Patrick W.B. Derksen,Emile E. Voest	2011	142
16	Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents Cancer Research ·Yuval Shaked,Terence Tang,Jill Woloszynek,Laura G.M. Daenen,Shan Man,Ping Xu,Shi-Rong Cai,Jeffrey M. Arbeit,Emile E. Voest,David J. Chaplin,Jon Smythe,Adrian L. Harris,Paul Nathan,Ian Judson,Gordon Rustin,Francesco Bertolini,Daniel C. Link,Robert S. Kerbel	2009	64
17	Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid Tumors Journal of Clinical Oncology ·Laurens V. Beerepoot,Sandra A. Radema,Els O. Witteveen,Sofia Kalatha,Catherine Wheeler,Sanford Kempin,Emile E. Voest	2006	89
18	Receptor protein tyrosine phosphatase mu expression as a marker for endothelial cell heterogeneity; analysis of RPTPmu gene expression using LacZ knock-in mice The International Journal of Developmental Biology ·Adria Keitel,Susana M. Chuva de Sousa Lopes,Büşra Tanır,Hans A.R. Bluyssen,Martin van der Valk,Emile E. Voest,Christine L. Mummery,Wouter H. Moolenaar,Martijn F.B.G. Gebbink	2003	30
19	Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands. PubMed ·W W ten Bokkel Huinink,C.J. van Groeningen,Emile E. Voest,W Peters,Michael Caffrey,J. Montogomery	2003	3
20	The discovery of new inhibitors of angiogenesis using an improved mouse corneal neovascularization model Investigative Ophthalmology & Visual Science ·P. Grauenfels,Emile E. Voest,Dmitri Vyacheslavovich Liventsev,Evelyn Flynn,Bryan Nicol,Rosario Amato	1995	2

About Emile E. Voest

Emile E. Voest is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Hepatology and Molecular Biology, having authored 370 papers that have together received 18.8k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (74 papers), Angiogenesis and VEGF in Cancer (55 papers), Cancer, Hypoxia, and Metabolism (51 papers), Colorectal Cancer Treatments and Studies (51 papers), Cancer Treatment and Pharmacology (47 papers), Lung Cancer Treatments and Mutations (31 papers), Cancer Cells and Metastasis (29 papers) and Cancer Immunotherapy and Biomarkers (21 papers). The work is most often cited by research in Cancer Research (4.9k citations), Oncology (8.5k citations), Hepatology (933 citations), Molecular Biology (7.3k citations) and Pulmonary and Respiratory Medicine (3.1k citations). Emile E. Voest has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Jeanine M.L. Roodhart, Martijn F.B.G. Gebbink, Alexander de Graeff, Saskia Teunissen, Krijn K. Dijkstra, René H. Medema, Rachel H. Giles, Judah Folkman, Martijn P. Lolkema and Robert J. D’Amato. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, British Journal of Cancer and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact